The changes in other plasma lipoproteins which accompany alterations in very low density lipoproteins (VLDL) were studied in 31 normal and hyperlipidemic men and women who underwent weight reduction, carbohydrate induction, or clofibrate treatment. Plasma lipids and individual lipoprotein cholesterol concentrations were measured serially during control and treatment periods. Low density lipoprotein (LDL) protein was determined by radial immunodiffusion. Oppositely directed changes in VLDL and LDL were found with each of the three metabolic perturbations. Changes in high density lipoprotein (HDL) cholesterol generally paralleled those in LDL but were less consistent. Two patients with type III hyperlipoproteinemia failed to demonstrate reciprocal increases in LDL despite more than 40% reduction in plasma glycerides or VLDL with weight reduction or clofibrate therapy. After clofibrate therapy, LDL increased in proportion to the absolute decrease in VLDL cholesterol during treatment. LDL protein changed relatively less than did LDL cholesterol. The mechanism for the interdependency of plasma VLDL and LDL concentrations over the long term is not known and may be the result of altered rates of interconversion of these lipoproteins, or to feedback inhibition by VLDL of LDL production and release. 
Inpatient studies were performed on the ward of the Clinical Research Center and were generally of 6 months duration. Inpatients were fed liquid formula diets supplemented with minerals and vitamins (7) . Basal formula diets consisted of 10% of calories as milk or soy protein, 50% of calories as carbohydrate (Dextri-maltose or Cerelose), and 40% fat calories. The latter were added as lard 'Abbreviations used in this paper: C/P, cholesterol-protein ratio; HDL, high density lipoprotein; LDL, low density lipoprotein; P/S, polyunsaturated/saturated fat ratio. given by mouth at a dose of 1 g twice daily.
Patients were bled after a 12-16 hr overnight fast; blood was collected in tubes containing disodium ethylenediaminetetraacetate (EDTA), 1 mg/ml of blood. Plasma was separated by low speed centrifugation at 4VC. Lipoprotein electrophoresis of whole plasma and of the supernates and infranates after ultracentrifugation at density 1.006 g/ml was performed on each sample to establish the lipoprotein phenotype and to confirm the ultracentrifugal separation of VLDL from HDL and LDL before lipoprotein quantitation. The diagnosis of type II hyperlipoproteinemia was made on the basis of a consistent elevation of LDL-cholesterol concentration in untreated patients. Patients with hyperprebetalipoproteinemia and hyperbetalipoproteinemia ("type II B") are specified in Table I .
Cholesterol and glycerides were measured by an AutoAnalyzer (8-10). The interassay coefficients of variation for replicate samples were 3.4%, n = 29 and 8.2%, n = 30 for cholesterol and glycerides, respectively. HDL cholesterol was measured directly in the supernate of plasma after precipitation of LDL and VLDL with dextran sulfate and calcium chloride (10 LDL-protein concentration was determined by radial immunodiffusion of plasma in agarose gel containing antiserum against human LDL prepared in rabbits. The concentration of LDL protein in unknown samples was obtained by comparison of the areas of the precipitin rings with those of a series of LDL standards for which the protein concentrations were known (11) . The cholesterol-protein ratio (C/P) was calculated as an index of LDL composition as reported elsewhere (11 Table II and Fig. 1 . Mean body weight did not change from control to induction periods (range 98.8-101.8% of control). Plasma glycerides and VLDL cholesterol rose 134 and 96.4%, respectively. Total cholesterol fell slightly. In each subject, cholesterol and LDL-C/P ratio fell (P < 0.01 and < 0.001, respectively). There was no consistent change in LDL-protein concentration (mean -9.0% from control mean, P> 0.1). HDL cholesterol fell 26% (P < 0.02).
Clofibrate treatment. 14 patients had undergone control and clofibrate treatment periods of sufficient duration to permit analysis (10-80 wk, Table II ). Control and treatment weights did not differ (mean treatment weights were 98.4 to 101.7% of control). 8 of the 14 experienced decreases in mean glyceride concentration of at least 40% from control values (Table II) . A representative study is shown in Fig. 2 (patient 15) . The responses of the two type III patients, 18 and 20, differed from the rest of the group despite comparable changes in plasma glycerides and VLDL cholesterol. In the type III patients, LDL cholesterol, LDL protein, and LDL-C/P ratio did not change appreciably. The remaining six of the eight responders had increases in mean LDL cholesterol (154%, P < 0.001), mean LDL protein (74.2%, P < 0.001), and mean LDL-C/P ratio (39.4%, P < 0.02) (Fig. 1) LDL-C/P ratio correlated with the absolute change in VLDL cholesterol concentration during clofibrate treatment for all except the two type III patients (Fig.  3) . The absolute changes in LDL cholesterol, LDL protein, and LDL-C/P also correlated significantly with the absolute change in VLDL cholesterol but to a lesser degree (r= -0.648, -0.572, and -0.785, respectively, all significant at P = 0.05). Thus the proportional changes in LDL cholesterol, LDL protein, and LDL-C/P were a function of the absolute fall in VLDL cholesterol. DISCUSSION These data show that reciprocal changes in the cholesterol content of plasma VLDL and LDL occur commonly, if not universally, in metabolic states which lead to substantial changes in plasma glycerides and VLDL. They define conditions during which reciprocal lipoprotein changes occur consistently, i.e., when drug treatment or dietary changes result in large absolute changes in VLDL cholesterol and plasma glycerides. Every subject with large absolute changes in VLDL cholesterol has shown this inverse relationship except those with type III hyperlipoproteinemia.
Throughout this study, changes in total plasma cholesterol were small and inconsistent despite marked changes in the relative concentrations of individual lipoprotein classes. These data re-emphasize that total plasma cholesterol, by itself, only poorly reflects changes in individual lipoprotein classes.
Reciprocal changes in LDL and VLDL have been noted by other workers in a variety of circumstances (12) (13) (14) . The fall in VLDL during dietary treatment of hyperlipemia by fat and caloric restriction was accompanied by reciprocal increases in LDL cholesterol, LDL protein, and LDL-C/P ratio in one report (14 (6) . The time relationships have been relatively short, several hours to a few days. Our measurements were made at weekly intervals and so do not exclude the possibility that similarly directed changes in VLDL and LDL concentration occurred in the immediate postperturbation period.
An inverse relationship between HDL (alpha lipoprotein) concentration and VLDL concentration has been found after carbohydrate induction (2), intravascular lipolysis (2), in vitro incubation of VLDL with postheparin plasma (15) , and clofibrate therapy (13) . Our data are generally in accord with these observations; plasma HDL concentration changed inversely with VLDL in most instances. There were, however, large differences in the absolute and relative changes in HDL between patients.
The physiologic basis for these reciprocal changes in plasma VLDL and LDL-cholesterol concentrations is not clear. At least two possibilities exist: first, these changes may reflect differences in the rates of conversion of VLDL to LDL. Thus, if conversion of VLDL to LDL were accelerated, as might occur with clofibrate treatment (16) (18) . Hepatic cholesterol synthesis, however, is subject to feedback inhibition by chylomicron cholesterol at the hydroxymethylglutarylCoA reductase step (19, 20) . If VLDL also have the capacity to inhibit hepatic cholesterogenesis, and if this process is rate-limiting in LDL synthesis and release, then LDL cholesterol and LDL-C/P would vary inversely with VLDL-cholesterol concentration. Moreover, the changes in LDL cholesterol and LDL-C/P would be expected to be more pronounced than those in LDL protein. Our data are in accord with such an hypothesis but do not exclude alternative possibilities.
This study confirms the failure of LDL concentration to change as VLDL falls during treatment in type III hyperlipoproteinemia (13) . From the limited number of patients studied thus far, the failure of VLDL-LDL reciprocity appears to be characteristic of this disorder and may provide further evidence for a defect in VLDL catabolism in type III (21) .
These data have several practical implications. During therapeutic weight loss or clofibrate administration, LDL-cholesterol concentration will often rise as VLDL falls. In some instances, hyperbetalipoproteinemia, a potentially more serious abnormality (22) , may result. Two patients in our series (15 and 19) showed LDL cholesterol increases to levels above defined normal limits (22) after clofibrate. In patient 15, LDL cholesterol gradually returned to normal. The other patient (19) died suddenly after 4 months of treatment. If total plasma cholesterol falls only slightly or even rises despite a significant drop in plasma glycerides during treatment of hyperlipidemia, the validity of such therapy should be reconsidered.
In the treatment of patients with type II hyperlipoproteinemia, one can make a rough prediction concerning the response of plasma LDL concentration to clofibrate therapy. Many patients with type II hyperlipoproteinemia and increased VLDL concentrations (type II B) will have an increase in plasma LDL concentration. In such cases, adjunctive or alternative drug therapy will probably be appropriate.
